Abstract | CONTEXT: OBJECTIVE: DESIGN AND SETTING: This was a case-control study. PATIENTS AND INTERVENTIONS: A total of 119 hyperthyroid patients and 108 healthy subjects were recruited. Of them, 41 hyperthyroid patients received thionamide treatment for 3 months until euthyroidism was obtained. MAIN OUTCOME MEASURES: Serum FGF21 levels were determined using the ELISA method. RESULTS: Serum FGF21 levels were significantly elevated in hyperthyroid patients as compared with normal subjects [median 290.67 (interquartile range, 156.60-502.33) vs 228.10 (169.85.25-320.10) pg/mL; P < .001]. After thionamide treatment, serum FGF21 levels in hyperthyroid patients declined markedly from 249.10 (139.10-444.00) to 106.90 (38.70-196.15) pg/mL (P < .001). Logistic regression revealed that FGF21, basal metabolic rate, low-density lipoprotein cholesterol, and alanine transaminase were significantly associated with hyperthyroidism. With adjustment for potential confounders, serum FGF21 remained independently associated with hyperthyroidism, with an adjusted odds ratio of 3.123 (95% confidence interval, 1.306-7.468) (P = .010). CONCLUSION:
|
Authors | Fangsen Xiao, Mingzhu Lin, Peiying Huang, Jinyang Zeng, Xin Zeng, Huijie Zhang, Xiaoying Li, Shuyu Yang, Zhibin Li, Xuejun Li |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 100
Issue 10
Pg. 3800-5
(Oct 2015)
ISSN: 1945-7197 [Electronic] United States |
PMID | 26241324
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antithyroid Agents
- fibroblast growth factor 21
- Fibroblast Growth Factors
|
Topics |
- Adult
- Antithyroid Agents
(therapeutic use)
- Case-Control Studies
- Female
- Fibroblast Growth Factors
(blood)
- Humans
- Hyperthyroidism
(blood, drug therapy)
- Insulin Resistance
- Male
- Treatment Outcome
- Young Adult
|